GreenLight Biosciences Holdings, PBC Common Stock
GRNA
GRNA was delisted on the 21st of July, 2023.
57 hedge funds and large institutions have $86.2M invested in GreenLight Biosciences Holdings, PBC Common Stock in 2022 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 31 increasing their positions, 5 reducing their positions, and 10 closing their positions.
520% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 5
70% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 10
32% more capital invested
Capital invested by funds: $65.2M → $86.2M (+$21M)
14% more funds holding
Funds holding: 50 → 57 (+7)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$8.64M |
| 2 |
Baird Financial Group
Milwaukee,
Wisconsin
|
+$7.48M |
| 3 |
BlackRock
New York
|
+$5.91M |
| 4 |
CGC
Continental Grain Company
New York
|
+$4.01M |
| 5 |
BNP Paribas Asset Management
Paris,
France
|
+$2.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VS
VK Services
Menlo Park,
California
|
-$11.5M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$2.32M |
| 3 |
Squarepoint
New York
|
-$181K |
| 4 |
HF
HRT Financial
New York
|
-$157K |
| 5 |
Two Sigma Investments
New York
|
-$68K |
GRNA Hedge Fund Activity: Q3 2022 in Review
57 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in GreenLight Biosciences Holdings, PBC Common Stock (GRNA) for Q3 2022, worth a combined $86.2M — up 32% from $65.2M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new GRNA positions and 10 closed out — a net gain of 7 holders — while 31 added to existing stakes and 5 trimmed.
The largest buyer was Cormorant Asset Management, adding an estimated $8.64M. The largest seller was VK Services, exiting entirely with an estimated $11.5M sold.
- 57 institutional investors held GreenLight Biosciences Holdings, PBC Common Stock (GRNA) as of Q3 2022, up from 50 in Q2 2022.
- Funds reported $86.2M of GreenLight Biosciences Holdings, PBC Common Stock stock for Q3 2022, up 32% quarter-over-quarter.
- 17 funds opened new GreenLight Biosciences Holdings, PBC Common Stock positions in Q3 2022 and 10 closed out, a net change of +7 holders.
- The largest GreenLight Biosciences Holdings, PBC Common Stock buyer in Q3 2022 was Cormorant Asset Management, an estimated $8.64M added.
- The largest GreenLight Biosciences Holdings, PBC Common Stock seller in Q3 2022 was VK Services, an estimated $11.5M sold.
Based on aggregated 13F filings for Q3 2022.